drugset
Drugs / MK-3682B
last change Sep 2017 re-read 9 days ago

MK-3682B

Developed for
chronic hepatitis C virus infection
Investigated by
Merck Sharp & Dohme LLC

Trials 1

today NCT02332720 · Ph 2
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02332720 Jan 2015 → Sep 2016 chronic hepatitis C virus infection Merck Sharp & Dohme LLC Completed No outcome recorded

News releases announcing trial results or a regulatory action · 3

DateIssuerRelease
2017-04-22 Merck Sharp & Dohme LLC Results Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C merck.com ↗
The study showed that 100 percent (43/43) of patients who completed 16 weeks of treatment plus ribavirin (RBV) achieved SVR12 and 100 percent (49/49) of patients who completed 24 weeks of treatment achieved SVR12 (abstract PS-159).
2017-04-05 Merck Sharp & Dohme LLC Results Merck to Present New Data on ZEPATIER® (elbasvir and grazoprevir) and Investigational Combination Therapy MK-3682B for the Treatment of Chronic Hepatitis C Infection at The International Liver Congress™ 2017 merck.com ↗
2016-11-13 Merck Sharp & Dohme LLC Results Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection merck.com ↗
Eight weeks of treatment with MK-3682B resulted in SVR12 rates of 95 percent, 86 percent and 95 percent in GT1, GT2 and GT3 patients, respectively.

All press releases naming this drug 4 releases

DateIssuerRelease

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MK-3682B ClinicalTrials.gov intervention name — accepted as the source's own label NCT02332720 ↗